Statistics

Total Visits

Views
The poor response to imatinib observed in CML patients with low OCT-1 activity is not attributable to lower uptake of imatinib into their CD34⁺ cells(legacy) 151
The poor response to imatinib observed in CML patients with low OCT-1 activity is not attributable to lower uptake of imatinib into their CD34⁺ cells(legacy) 103

Total Visits per Month

January 2024 February 2024 March 2024 April 2024 May 2024 June 2024 July 2024
The poor response to imatinib observed in CML patients with low OCT-1 activity is not attributable to lower uptake of imatinib into their CD34⁺ cells 4 2 6 4 8 3 0

File Downloads

Views

Top Country Views

Views
United States 88
China 16
Vietnam 12
France 11
Netherlands 8
Australia 7
Singapore 7
Argentina 4
Canada 1
Ireland 1

Top City Views

Views
Ashburn 23
Hanoi 12
Buffalo 10
Rotterdam 8
Cambridge 6
Fairfield 6
Kaleen 6
Singapore 6
Zhengzhou 6
New York 4